UCB SA is divesting its mature neurology and allergy business in China, selling those products to CBC Group and Mubadala Investment Co. for $680 million so it can refocus on innovation and partnerships in China. The deal includes UCB’s manufacturing site in Zhuhai in Guangdong province.
Tamra Sami is a science writer, editor, and publication manager with expertise in product development, particularly in Asia and emerging markets. As a staff writer for Bioworld co., Tamra focuses on covering a wide range of topics in the field of biotechnology, including advancements in precision health, clinical trial results, licensing deals, and emerging therapies.